Analyst Irina Koffler from Mizuho Securities reiterated her Buy rating on Jazz Pharmaceuticals plc (NASDAQ:JAZZ) with a raised price target of $195, marking a 37% increase from current levels. The ranking came ahead of Jazz’s 2Q earnings release. The analyst is expecting revenues of $361.7 million and EPS of $2.76. Koffler is also optimistic about “Xyrem litigation/settlements and stronger than expected performance of Defitleio in the U.S.”
According to TipRanks, Koffler has a success rate of 59% with an average return of 24.9% per recommendation.